Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
Fast Company November 2013 Elizabeth Murphy	To Know You Is To Really Know You A deeper look at the makeup of genetic testing firm 23andme's customers and what their DNA reveals.
BusinessWeek October 23, 2008 John Carey	Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon.
Fast Company David Lumb	The FDA Just OK'd 23AndMe To Test For One Syndrome The FDA just gave consumer genetics testing company 23AndMe permission to sell tests for Bloom syndrome -- a disease associated with shortened height and an increased cancer risk.
Wired November 17, 2007 Thomas Goetz	23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
Fast Company Elizabeth Segran	23andMe And The FDA Reached A Pivotal Genetic Testing Agreement An FDA decision summary allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that may lead toward the development of cancer.
IEEE Spectrum March 2013 Eliza Strickland	The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine
Fast Company December 1, 2007 Amanda Bower	Are There Holes In My Genes? A new industry promises to gauge your genetic risk of getting diseases like cancer. Its investors, including John Doerr's Kleiner Perkins and Mark Kvamme's Sequoia Capital, have bet millions that consumers will buy it. Here, the author takes a test.
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
Entrepreneur February 2009 Dennis Romero	DNA Testing: A Growth Market The barriers to entry are daunting, but the DNA market provides opportunities.
Fast Company September 2000 John Ellis	The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning.
Chemistry World February 25, 2015 Rebecca Trager	US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests.
HHMI Bulletin May 2012 Sarah C. P. Williams	Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
The Motley Fool February 2, 2010 Brian Orelli	Shaking Up the Biotech Industry A judge will decide if genes are patentable or not.
HHMI Bulletin May 2012 Sarah C. P. Williams	Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies.
Chemistry World June 6, 2007 Simon Hadlington	Large-Scale Gene Scanning for Common Diseases A multi-center genome scanning project that has analyzed half a million genetic markers in thousands of healthy people and people with a range of common diseases has revealed previously unknown genetic variants of the diseases.
Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
Fast Company November 2013 Elizabeth Murphy	Inside 23andMe founder Anne Wojcicki's $99 DNA Revolution If Wojcicki gets it right, 23andMe could help change the health care industry as we know it. "At $99, we are opening the doors of access," she says. "Genetics is part of an entire path for how you're going to live a healthier life."
Fast Company David Lumb	Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
Managed Care May 2001 Michael D. Dalzell	Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use...
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Chemistry World July 13, 2011 Hayley Birch	Naked mole-rat genome holds clue to beating cancer The recently published draft sequence of the naked mole-rat genome promises to reveal the secrets of its long and remarkably cancer-free existence, potentially providing new targets for anti-cancer drugs.
IEEE Spectrum March 2013 Susan Hassler	Genome to Go It's already possible to have your own genome sequenced. But personalized medicine based on sequencing still has a way to go
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Fast Company Pavithra Mohan	App Used 23andMe's DNA Database To Block People From Sites Based On Race And Gender Personal genetics company 23andMe discovered that a programmer had used its open API to create a screening mechanism for websites -- which could effectively block people by race, sex, and ancestry.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
IEEE Spectrum February 2010 Mark Anderson	Genome as Commodity In a few years, millions will have purchased their own genome. The cultural ramifications of a $100 genome are as wide and deep as those of any other recent innovation, including search engines and cellphones.
BusinessWeek January 21, 2010 Rich Jaroslovsky	Web DNA Tests Offer Ease and Enlightenment A comparison of the often entertaining services of Navigenics, 23andMe, and deCODEme.
AskMen.com Jacob Franek	Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs?
Fast Company John Paul Titlow	23andMe Wants To Turn Your DNA Data Into Lucrative New Drugs 23andMe's original business model may have been thwarted by the feds, but that isn't stopping the company from trying new ways to generate revenue. Its latest idea could be a lucrative one: invent new drugs.
Chemistry World April 3, 2008 Lewis Brindley	DNA Read in a Trice The prospect of treatments that are tailored to fit an individual's genetic makeup is a step closer thanks to technology unveiled by US scientists.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
Bio-IT World October 9, 2002 Malorye Branca	The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response.
BusinessWeek May 9, 2005 John Carey	Dr. Francis S. Collins: On The Trail Of Disease Genes Collins is leading the search for DNA variations that can result in illnesses.
The Motley Fool August 26, 2009 Brian Orelli	This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half.
AskMen.com Ross Bonander	5 Things You Didn't Know: DNA With human cloning and other controversial bombshells waiting just around the corner, expect DNA to remain in the public eye for decades to come.
Salon.com June 26, 2000 Ralph Brave	The great gene race A tiny private company and the giant public genome project jointly crossed the finish line. But the upstart really won.
Science News April 24, 2004	DNA Day An ivitation to commemorating the completion of the Human Genome Project in 2003 and the description of DNA's structure as a double helix in 1953.
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
Popular Mechanics April 25, 2008 Erik Sofge	Inside the Forgotten X Prize--the One That Can Save Your Life An extensive look at the Archon X Prize in Genomics, the $10 million race for a cheap, disease-hunting gene sequencer that could land on your kitchen counter sooner than you think.